Vulcabras: Revenue Streak Holds, Earnings Under Debt Drag — Valuation Still Compelling

Vulcabras (BVMF:VULC3) reported its 23rd consecutive quarter of revenue growth in Q2 2026, posting R$994.8 million of net sales — an 11.2% increase from a year earlier. Earnings per share of R$0.46 missed the consensus forecast of R$0.48, and fell from R$0.51 a year ago. The stock trades at roughly 3.5 times trailing earnings. The mismatch between the company's growth trajectory and its multiple is the story here. The question is whether the current earnings drag from interest costs is a transitional weight or a permanent one.

I am rating this a Buy. The revenue engine is intact, margins are holding, net debt is coming down, and the market is pricing Vulcabras as if that growth streak is about to break. It is not.

What changed in Q2

Revenue hit R$994.8 million, beating analyst expectations of R$993 million and marking the 23rd straight quarter of top-line growth. Recurring EBITDA... rose 9.3% to R$208.6 million. Recurring net income of R$143.7 million dipped just 0.8% year-over-year.

EPS missed, but the miss tells a debt story, not a business story. Vulcabras took on significant loans and debentures in 2025 to fund a R$1.5 billion dividend distribution and capital expenditure. In Q1 2026, net financial costs swung from a R$2.3 million gain a year earlier to a R$27.8 million charge. With Brazil's Selic benchmark rate at 15%, that debt load is expensive. The Q2 EPS miss versus the R$0.48 consensus is the interest bill doing its work, not the footwear business slowing.

Revenue neared the symbolic R$1 billion quarterly mark for the first time. That matters because it confirms the company's growth path is not stalling as it approaches a higher run-rate.

The operating picture: growth, margins, brand mix

The underlying business is running well. Gross margins have held in the 40-41% range, up from roughly 39.4% on average through 2023. That stability is not automatic — the company faced higher payroll taxes from Brazil's reinstated contribution program, a statutory minimum wage increase, elevated absenteeism, and rising raw material and packaging costs. The fact that gross margin ticked up rather than down means pricing and production discipline are absorbing the pressure.

Brand execution is the engine. Under Armour is the fastest-growing name in the portfolio, driven by performance running lines including the Nonstop, Endless, and Velociti Elite 3. Olympikus, Vulcabras' own running brand, is Brazil's top domestic running label and launched its first locally-conceived ultra-running shoe (Corre Pace) in 2025, expanding into a niche where foreign brands have dominated. Mizuno is extending its competitive range. The company controls manufacturing at a large complex in Horizonte, Ceará, which shields it from import-cost swings when the real weakens — a recurring currency risk for import-dependent competitors.

Athletic footwear accounts for roughly 84% of revenue. Volume grew 10.5% in Q1, supported by capacity from a 2025 plant expansion. Apparel and accessories are a smaller but rising category, up 2.8% in Q1.

The debt drag and the path off it

Net debt stood at R$658.9 million as of March 31, 2026, down R$110.5 million from year-end 2025's R$769.4 million. That is the critical data point. The debt level is falling, which means the interest burden that crushed Q1 and weighed on Q2 EPS should ease sequentially. At 15% Selic, every R$100 million of debt reduction saves roughly R$15 million in annual interest cost — a direct line to EPS recovery.

The board also approved a new share repurchase program for up to 15 million shares, roughly 13.6% of the free float. A buyback of this scale at a 15% risk-free rate signals that management views the stock as a better deployment of capital than parking cash or paying down debt. It also narrows the share count, mechanically lifting EPS as interest costs come down.

Valuation

Vulcabras closes near R$14.07, trading at approximately 3.5 times trailing earnings and around 6.9 times forward estimates. The peer average P/E for Brazilian consumer durables is roughly 7.6x. Vulcabras is trading at less than half that average while growing revenue at 11% and expanding EBITDA at nearly 10%.

UBS maintains a Buy rating with a R$23 price target — roughly 64% upside from current levels. Analyst consensus revenue estimates run around R$1.01 billion to R$1.08 billion for the next two quarters, with full-year projections pointing toward R$1.22 billion by mid-2027, implying top-line growth well above 50% over the period.

The 3.5x trailing P/E is not a valuation reset reflecting permanent business damage. It is a temporary discount for a debt-fueled earnings trough. As interest costs decline with the falling net debt balance, the multiple should expand back toward its forward estimate of roughly 6.9x and eventually toward the peer average. That is a mechanical re-rating path, contingent on the debt paying down as it has been.

Risks

Three risks keep this from being a free shot. First, if Brazil's consumer credit conditions deteriorate — the Selic rate at 15% is punishing for leveraged households — athletic footwear could see a demand pullback. The sector is not immune to a consumer slowdown, even if running and health-related spending has shown resilience. Second, the R$659 million net debt balance is still meaningful relative to quarterly revenue. A further rise in rates, or a stalling revenue trajectory, could reverse the de-leveraging trend. Third, the buyback of up to 13.6% of free float is ambitious, and there is no guarantee it executes fully or at favorable levels. If the company deploys too much capital on buybacks while interest costs remain elevated, the balance sheet could come under strain.

Investor takeaway

Vulcabras is growing revenue at 11% for the 23rd straight quarter, maintaining gross margins above 40%, bringing net debt down, and trading at 3.5 times trailing earnings. The Q2 EPS miss was an interest-cost problem, not a business problem. The debt is the bridge between today's cheap valuation and the earnings recovery that follows. With net debt falling, a large buyback approved, and revenue pushing toward R$1 billion per quarter, the risk/reward is asymmetric.

I rate Vulcabras a Buy. The metrics that would change my view are a break in the revenue growth streak, a reversal in the net debt trajectory, or gross margins falling below 38%. None of those signals are present today. The next catalyst is Q3 results, expected around November 10, 2026, where the market will see whether interest costs continue their expected decline and whether the revenue engine extends its streak.